摘要
重组人脑利钠肽(Recombinant Human Brain Natriuretic Peptide,rh-BNP)是利用基因重组技术制成的冻干粉制剂,与内源性脑利钠肽具有相同的氨基酸排序、分子结构,具有促进尿钠排泄、利尿、舒张动静脉系统平滑肌、抑制肾素-血管紧张素-醛固酮系统等作用,在使心力衰竭特别是急性失代偿性心力衰竭(acute decompensated heart failure,ADHF)患者获益的同时不增加肾功能恶化的风险,因此亦被应用于心肾综合征,急性心肌梗死伴心力衰竭行急诊经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的患者,能有效减少肾功能恶化的发生。多项研究表明rh-BNP无益于降低远期再入院率和死亡率,但联合应用左西孟旦、参附注射液等能有效改善远期预后,并减少严重低血压等不良事件的发生。此文目的在于阐述rh-BNP的临床应用进展。
Recombinant Human Brain Natriuretic Peptide (rh-BNP)is a lyophilized powder preparation made by genetic recombination technology.It has the same amino acid sequence and molecular structure as endogenous brain natriuretic peptide,and has the functions of promoting urinary sodium excretion,diuresis,diastolic arteriovenous smooth muscle,and inhibition of renin-angiotensin-aldosterone system.It does not increase the risk of worsening renal function while benefiting patients with heart failure,especially acute decompensated heart failure (ADHF).Therefore,it is also used in patients with cardio-renal syndrome,acute myocardial infarction and heart failure undergoing emergency percutaneous coronary intervention (PCI),which can effectively reduce the occurrence of renal function deterioration.Multiple studies have shown that rh-BNP is not conducive to reducing long-term readmission rates and mortality. However,the combined application of levosimendan and Shenfu injection can effectively improve the long-term prognosis and reduce the occurrence of adverse events such as severe hypotension.The purpose of this article is to illustrate the clinical application of rh-BNP.
作者
郎文
姜钧文
LANG Wen;JIANG Junwen(Liaoning University of Traditional Chinese Medicine Liaoning Shenyang 110032,China;The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine Liaoning Shenyang 110032,China)
出处
《中医药临床杂志》
2019年第1期188-191,共4页
Clinical Journal of Traditional Chinese Medicine
关键词
重组人脑利钠肽
心力衰竭
造影剂肾病
Recombinant Human Brain Natriuretic Peptide
Heart failure
Contrast-induced nephropathy
